Irreversible electroporation treatment in patients with pancreatic locally advanced adenocarcinoma - IMPALA

Academisch Medisch Centrum0 个研究点目标入组 50 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•- Age 18 years or older
•- Capable of providing written and oral informed consent
•- Physically fit to undergo explorative laparotomy
•- Pancreatic cancer confirmed with pathology (either pre- or intraoperative, pathological diagnosis must be either pancreatic adenocarcinoma or non-intestinal cholangiocarcinoma located in the pancreas) and non resectability because of locally advanced growth (stage III) during surgical exploration
•- One of the following:
•* Potentially resectable panreatic cancer based on imaging and planned for surgical exploration with intend for resection, this includes 2 groups of patients
•* Patients with resectable disease at primary evaluation but are considered non-resectable during surgical exploration
•$ Patients with initially non-resectable disease because of locally advanced pancreatic cancer without metastases, who have stable or regressive (non-metastasized) disease after 3 months of chemotherapy
•* Locally advanced pancreatic cancer based on imaging without options for non-operative drainage of stomach and bileducts and therefore planned for surgical exploration with intend for bypass surgery

•- Resectable pancreatic cancer during explorative laparotomy
•- Presence of metastatic disease (peritoneal, liver or other)
•- Pathological diagnosis of intestinal-type cholangiocarcinoma
•- History of cardiac arrhythmia*s
•* Sinus tachycardia (BPM>100)
•* Sick sinus syndrome
•* Sinoatrial exit block
•* AV block
•* Sinus node reentry
•* Presence of a pacemaker or defibrillator
•- Recent history of myocardial infarction
•- History of epilepsy
•- Partial portal vein thrombosis
•- Both narrowing (sclerosis) of the portal vein and a reduced diameter of either the common hepatic artery, celiac trunc or superior mesenteric artery of >50%

发起方